172 results on '"Werutsky G"'
Search Results
2. Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
3. P263 Patients’ perspectives on treatments for HR+/HER2– early breast cancer: developing a quantitative patient preference survey
4. 42 Social and economic impact of cervical cancer in brazil: analysis of EVA/EVITA cohort study (LACOG 0215)
5. OA12.06 Intensified Chemo-Immuno-Radiotherapy with Durvalumab for Stage III NSCLCs: A Single Arm Phase II Study - PACIFIC-BRAZIL (LACOG 2218).
6. EP03.01-003 Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
7. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
8. PO-1230 Delay in postoperative radiation in pts with breast cancer in Brazil: a sub-analysis of AMAZONA III
9. 811P Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
10. HPR90 Sustainability of Biosimilars Medicines Policies in Brazil
11. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
12. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials
13. EP1.16-39 Prospective Epidemiological Study of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America – LATINO Lung (LACOG 0116)
14. P1.09-02 Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer in Brazil (GBOT 0118/LACOG 0418)
15. 42 Social and economic impact of cervical cancer in brazil: analysis of EVA/EVITA cohort study (LACOG 0215)
16. Abstract P4-12-01: Not presented
17. Abstract P1-08-27: Advanced stage at diagnosis and worse clinicopathologic features in young woman with breast cancer. A sub-analysis of Brazilian population through the AMAZONA III study (GBECAM 0115)
18. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
19. P1.01-23 High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?
20. P2.13-09 Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials
21. The AMAZONA Project: Retrospective Cohort Study Describing Breast Cancer Patients' Characteristics and Survival in Brazil
22. Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
23. Imunotherapy in clinical practice: Real world multicentric Brazilian experience
24. PD.2.02 Central Nervous System (CNS) Metastasis in Patients with T790M EGFRm Lung Cancer – Real World Data from a Brazilian Cohort
25. Impact in delay of starting chemotherapy and surgery on pCR/survival in breast cancer (BC)-pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials
26. Abstract P4-10-17: Survival outcomes related to health care coverage in metastatic breast cancer in Brazil: A sub-analysis from the LACOG-0312 study
27. Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program
28. Abstract P1-17-10: Survival outcomes related to health care coverage in breast cancer patients with brain metastases in Brazil: A sub-analysis from the LACOG-0312 study
29. Abstract P6-08-24: Reproductive status and clinical pathological characteristics of young women diagnosed with breast cancer in Latin America: LACOG 0414 study
30. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
31. P3.16-034 Impact of Travel Distance to Treatment Institution on Survival from Stage I to III Lung Cancer
32. P1.01-043 Molecular Testing for Non-Small Cell Lung Cancer in Latin American
33. P1.01-063 Are the Real World Patients with Advanced Non-Small Cell Lung Cancer Represented in Phase III Immunotherapy Trials?
34. Abstract P6-16-04: Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study
35. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
36. 188P - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials
37. The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the future
38. Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
39. 1233P - Imunotherapy in clinical practice: Real world multicentric Brazilian experience
40. 978P - Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
41. Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial
42. Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
43. Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)
44. Abstract P1-09-06: Breast cancer in the Pan-American region: Inequities in incidence and mortality rates according to the human development index
45. 93. Local excision with or without radiotherapy in ductal carcinoma in situ – Treatment and prognosis after a recurrence
46. OC-0134 LOCAL EXCISION WITH OR WITHOUT RADIOTHERAPY IN DUCTAL CARCINOMA IN SITU: TREATMENT AND PROGNOSIS AFTER A RECURRENCE
47. 211 Phase III Trial (EORTC 10801) Comparing Breast-conserving Therapy with Radical Mastectomy – Twenty Year Follow-up Results
48. 412 The EORTC 10041/BIG 03-04 MINDACT Trial Quality Assurance Program – Results of the Questionnaire for Pathologists
49. 493 Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial
50. 217 Adjuvant Radiotherapy After Breast-conserving Surgery for Ductal Carcinoma in Situ – Fifteen-year Results of the EORTC Randomized Phase III Trial 10853
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.